News Agency
The Times

Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston

  • Written by PR Newswire
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston

Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases

SYDNEY, Oct. 13, 2023 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) CEO Dr Steven...

Read more: Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and...

Why Shopify Web Development Is Important For Modern Online Stores

A successful online store requires more than attractive product images and basic functionality. Businesses need websites that load quickly, provide smooth navigation, and create a reliable shopping experience across all devices. Professional Shopify web development helps businesses build scalable eCommerce stores... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion